Navigation Links
Rutgers receives $2.3 million federal grant to research use, safety of antipsychotics
Date:10/21/2008

NEW BRUNSWICK, N.J. Rutgers, The State University of New Jersey, has received a $2.3 million grant from the federal Agency for Healthcare Research and Quality (AHRQ) and the Food and Drug Administration (FDA) to lead a major study of use, safety and effectiveness of antipsychotic medications.

These medications have come to be widely used in a clinically diverse population, including many children and adolescents with such behavioral disorders as aggression and elderly persons with symptoms of dementia, as well as adults with schizophrenia and other serious mental illnesses. Use of antipsychotic medications has increased and broadened with the advent of newer, "atypical" antipsychotic drugs perceived as safer than older drugs, according to principal investigator Professor Stephen Crystal of Rutgers' Center for Health Services Research on Pharmacotherapy, Chronic Disease Management, and Outcomes.

However, as the AHRQ and FDA noted in their request for applications, evidence remains incomplete on safety and effectiveness in various subpopulations of patients treated with these medications, Crystal said. Areas of particular concern include use in youth and in the elderly. Crystal, whose center is a unit of the Institute for Health, Health Care Policy and Aging Research (IHHCPAR), said that Harvard Medical School/Brigham and Women's Hospital, Vanderbilt University and Columbia University are partners in the Rutgers-led consortium.

Investigative teams will conduct three substudies using large, linked health care datasets. The first will focus on outcomes in the institutionalized elderly to examine medical outcomes, such as mortality, stroke, myocardial infarction, as well as cognitive function and behavioral symptoms of dementia. The Rutgers team will expand a research dataset developed through the AHRQ-funded Center for Education and Research on Mental Health Therapeutics, to support analyses by Harvard and Rutgers investigators on medication outcomes on several million nursing home residents across the nation.

A second substudy, examining medication outcomes for children and adolescents, will combine analyses of Medicaid claims, medical charts and electronic medical record data in Tennessee (led by Vanderbilt investigators) with Rutgers-based analyses of national Medicaid data. The third substudy will examine several populationwide safety issues across the age spectrum, including risks of pituitary tumors, diabetes and outcomes for elderly with dementia who live in the community.

"The initiative by AHRQ and the FDA to fund this study represents a significant step forward in helping to provide better information on the outcomes of therapies that are used by large numbers of elderly persons, youth and other patients," Crystal said.

"We are very pleased that the important program of work at the institute on the use and outcomes of mental health medications has been recognized by this award," added Professor David Mechanic, director of the IHHCPAR.


'/>"/>

Contact: Steven Manas
smanas@ur.rutgers.edu
732-932-7084
Rutgers University
Source:Eurekalert

Related medicine news :

1. Rutgers research identifies brain cells related to fear
2. NYU, Rutgers study shows how using mental strategies can alter the brains reward circuitry
3. Rutgers scientist receives prestigious Young Investigator Award
4. Rutgers researchers show how the brain can protect against cancer
5. The Healthcare Foundation of NJ awards grant to Rutgers College of Nursings Rachel Jones
6. 2 Rutgers College of Nursing Ph.D students to receive FNSNA Fellowships
7. Rutgers College of Nursings Linda Flynn to receive N.J. Governors Nursing Merit Award
8. Rutgers research partner Stemcyte, Inc., expands to New Jersey
9. The Zonta Club of Essex County honors Rutgers College of Nursings Rachel Jones
10. Julia Quinlan to present awards at a conference hosted by Rutgers College of Nursing
11. Rutgers researchers unlock mysteries of vitamin A metabolism during embryonic development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... The president released a ... Health System but would shift more of the cost burden to military beneficiaries. ... laid out in the defense budget as including limited quantifiable benefit fixes mixed with ...
(Date:2/11/2016)... ... February 11, 2016 , ... In a new paper ... surgeon , Dr. Rod J. Rohrich, and colleagues, examine and underscore the importance ... for rhinoplasty surgeons when addressing this vital area. , The upper lateral cartilage ...
(Date:2/11/2016)... ... 11, 2016 , ... PharmMD CEO Robert Yeager ... focus on contract negotiations, corporate strategy and healthcare data law. Additional responsibilities will ... in data breaches for the Part D Star Rating improvement and Medication Therapy ...
(Date:2/11/2016)... ... February 11, 2016 , ... Talix ... Family Practice , will be presenting at the 2016 HIMSS Annual Conference & ... , During his session, “ Coding for Care: Using Data Analytics for ...
(Date:2/11/2016)... ... 2016 , ... Be Well Medical Group (Be Well) is pleased ... at 108 South Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group is ... the convenience of their homes, offices or at the practices’ local office. It is ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016   ... the advancement of new health technologies, announced today " ... outstanding achievements in health tech over the past ten ... For nearly a decade, Health 2.0 has served ... and showcased and connected with thousands of technologies, companies, ...
(Date:2/11/2016)... Feb. 11, 2016 AAIPharma Services Corp./Cambridge ... custom manufacturing and development services for the pharmaceutical ... capabilities and capacity in its Charleston, ... has driven several recent investments. ... one filling line with small-scale lyophilization. The site ...
(Date:2/11/2016)... de 2016  A Proliant Biologicals anuncia, com ... bovina (BSA -- Bovine Serum Albumin ) ... Norte da Nova Zelândia, em Feilding. ... da Proliant nos EUA, localizada em ... dos equipamentos foram feitos de forma a reproduzir ...
Breaking Medicine Technology: